CRISPR Therapeutics vs Heartflow
CRISPR Therapeutics (CRSP), health care, and Heartflow (HTFL), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Heartflow is worth $4.1B on the stock market and CRISPR Therapeutics $3.9B: Heartflow is valued at 6% more. CRISPR Therapeutics's operating margin in its latest fiscal year was -18934% and Heartflow's -36.4%. Over the past year CRISPR Therapeutics's share price has moved -24.5% and Heartflow's +71.6%.
Key facts
- CRISPR Therapeutics market value
- $3.9B
- Heartflow market value
- $4.1B
- Heartflow P/E
- 70.3
- CRISPR Therapeutics revenue
- $3.5MFY to 2025-12-31
- Heartflow revenue
- $176MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | CRISPR Therapeutics | Heartflow |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $3.9Blower | $4.1Bhigher |
| Revenue | $3.5Mlower | $176Mhigher |
| Earnings | -$581.6Mlower | -$116.8Mhigher |
| Employees | — | 843 |
| Total assets | $2.3Bhigher | $359.5Mlower |
| Valuation | ||
| P/E | — | 70.3 |
| P/S | 1110higher | 23.5lower |
| P/B | — | 14.6 |
| Dividend yield | — | 0.00% |
| Profitability | ||
| Operating margin | -18934%lower | -36.4%higher |
| Balance sheet | ||
| Net assets | $1.9Bhigher | $300.6Mlower |
| Total liabilities | $343.4Mhigher | $58.8Mlower |
| Total debt | — | — |
| Cash on hand | $347.6Mhigher | $44.8Mlower |
| Price change | ||
| Today | -0.54%lower | +0.45%higher |
| 1 year | -24.5%lower | +71.6%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
CRISPR Therapeutics only (1)
- Cathie Wood3.2%
Heartflow only (3)
- Ron Baron0.2%
- Polen Capital team<0.1%
- Temasek<0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns CRSP · Who owns HTFL
More on CRISPR Therapeutics
Further comparisons
CRISPR Therapeutics against its closest peers
Heartflow against its closest peers
Learn
Questions and answers
Which is bigger, CRISPR Therapeutics or Heartflow?
By market value, Heartflow is the larger: $4.1B against $3.9B for CRISPR Therapeutics. By revenue in its latest fiscal year, Heartflow is the larger: $176M against $3.5M for CRISPR Therapeutics.
Which has the higher operating margin?
Heartflow: -36.4%, against -18934% for CRISPR Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both CRISPR Therapeutics and Heartflow?
None of the tracked superinvestors holds both in their latest 13F filing. 1 holds CRISPR Therapeutics and 3 hold Heartflow.
Cite this page
Funkfolio, “CRISPR Therapeutics vs Heartflow”, data as of 18 November 2026. https://funkfolio.com/compare/crsp-vs-htfl
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.